• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)

    10/20/21 3:42:52 PM ET
    $ADMS
    Major Pharmaceuticals
    Health Care
    Get the next $ADMS alert in real time by email
    SC 13G/A 1 sc13-ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Amendment No. 1

     

    Under the Securities Exchange Act of 1934

     

      Adamas Pharmaceuticals, Inc.  
      (Name of Issuer)  
         
     

    Common Stock, $0.001 par value per share

     
      (Title of Class of Securities)  
         
      00548A106  
      (CUSIP Number)  
         
      October 11, 2021  
      (Date of Event Which Requires Filing of this Statement)  
         

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 00548A106

     

    1.

     Names of Reporting Persons. AIGH Capital Management, LLC

     I.R.S. Identification Nos. of above persons (entities only).

     

     27-4413262

    2.

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐

     (b) ☒

    3.

     SEC Use Only

     

     

    4.

     Citizenship of Place of Organization

     

     Maryland

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

     Sole Voting Power

     

     0

      6.

     Shared Voting Power

     

     

      7.

     Sole Dispositive Power

    0

     

      8.

     Shared Dispositive Power

     

     

    9.

     Aggregate Amount Beneficially Owned by each Reporting Person

     

     0

    10.

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

     Percent of Class Represented by Amount in Row 9

     

     0%

    12.

     Type of Reporting Person (See Instructions)

     

     OO

           

     
     

     

    CUSIP No. 00548A106

     

    1.

     Names of Reporting Persons. AIGH Investment Partners, L.L.C.

     I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐

     (b) ☒

    3.

     SEC Use Only

     

     

    4.

     Citizenship of Place of Organization

     

     Delaware

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

     Sole Voting Power

     

     0

      6.

     Shared Voting Power

     

    0

      7.

     Sole Dispositive Power

     

     

      8.

     Shared Dispositive Power

     

     

    9.

     Aggregate Amount Beneficially Owned by each Reporting Person

     

     

    10.

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

     Percent of Class Represented by Amount in Row 9

     

     

    12.

     Type of Reporting Person (See Instructions)

     

     OO

           

     
     

     

    CUSIP No. 00548A106

     

    1.

     Names of Reporting Persons. Orin Hirschman

     I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐

     (b) ☒

    3.

     SEC Use Only

     

     

    4.

     Citizenship of Place of Organization

     

     United States

    Number of Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

     Sole Voting Power

     

     0

      6.

     Shared Voting Power

     

     

      7.

     Sole Dispositive Power

     

     0

      8.

     Shared Dispositive Power

     

     

    9.

     Aggregate Amount Beneficially Owned by each Reporting Person

     

     0

    10.

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

     Percent of Class Represented by Amount in Row 9

     

    0%

    12.

     Type of Reporting Person (See Instructions)

     

     IN

           

     
     

     

    ITEM 1:

     

    (a) Name of Issuer:

     

    Adamas Pharmaceuticals, Inc.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    1900 Powell Street, Suite 1000

    Emeryville, California 94608

     

    ITEM 2:

     

    (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

    (i)   AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH LP”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P. and WVP Emerging Manger Onshore Fund, LLC;
         
    (ii)  

    AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

         
    (iii)   Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held by AIGH LP, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Investment Partners, L.P., AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d) Title of Class of Securities:

     

    Common Stock, par value $0.001

     

    (e) CUSIP Number:

     

    00548A106

     

     
     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

       (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 20, 2021 By: /s/ Orin Hirschman
        Orin Hirschman,
        Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.

     

     

    Get the next $ADMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMS

    DatePrice TargetRatingAnalyst
    11/17/2021$8.50Outperform → Market Perform
    Northland Capital Markets
    10/12/2021Market Outperform → Market Perform
    JMP Securities
    10/12/2021$7.00 → $8.00Overweight → Neutral
    Piper Sandler
    10/12/2021$10.00 → $9.10Buy → Neutral
    HC Wainwright & Co.
    10/11/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ADMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bigham Michael closing all direct ownership in the company

      4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)

      11/24/21 4:11:37 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Mahoney David L closing all direct ownership in the company

      4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)

      11/24/21 4:11:16 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company

      4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)

      11/24/21 4:10:18 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adamas Pharmaceuticals downgraded by Northland Capital Markets with a new price target

      Northland Capital Markets downgraded Adamas Pharmaceuticals from Outperform to Market Perform and set a new price target of $8.50

      11/17/21 7:40:51 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • Adamas Pharmaceuticals downgraded by JMP Securities

      JMP Securities downgraded Adamas Pharmaceuticals from Market Outperform to Market Perform

      10/12/21 6:50:59 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • Adamas Pharmaceuticals downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Adamas Pharmaceuticals from Overweight to Neutral and set a new price target of $8.00 from $7.00 previously

      10/12/21 6:47:58 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

      ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r

      11/24/21 9:12:51 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

      ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer (as defined below). The Off

      11/23/21 8:00:00 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

      Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),

      10/11/21 6:30:00 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ADMS
    SEC Filings

    See more
    • SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.

      15-12B - Adamas Pharmaceuticals Inc (0001328143) (Filer)

      12/6/21 5:25:20 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.

      EFFECT - Adamas Pharmaceuticals Inc (0001328143) (Filer)

      12/2/21 12:15:24 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Adamas Pharmaceuticals, Inc.

      S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)

      11/24/21 11:53:45 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)

      SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)

      12/10/21 8:52:22 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)

      SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)

      10/20/21 3:42:52 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by Adamas Pharmaceuticals, Inc.

      SC 13D - Adamas Pharmaceuticals Inc (0001328143) (Subject)

      10/19/21 4:26:46 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Financials

    Live finance-specific insights

    See more
    • Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

      ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r

      11/24/21 9:12:51 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

      Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),

      10/11/21 6:30:00 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Adamas Reports Second Quarter 2021 Financial Results

      Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights. "We delivered a strong performance in the second quarter, with a robust increase in demand set to fuel future growth," said Neil F. McFarlane, Chief Executive Officer. "We remain on track to achieve our 2021 goals as we navigate the

      8/9/21 4:01:00 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care